Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Amy Sainski"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jerzy E. Tyczynski, Lia Gutierrez, Rishi Deka, Amy Sainski, Junjie Ma, Tapashi Dalvi, David D. Stenehjem, Casey R. Tak, Marisa B. Schauerhamer, Claire Telford, Joseph Biskupiak, James A. Kaye, Sudhir Unni, Diana I. Brixner, Hillevi Bauer, Xiangyang Ye
Publikováno v:
Breast Cancer Research and Treatment. 186:839-850
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Autor:
Briain O Hartaigh, Xue Song, Jessica Franchino-Elder, Adrienne Gilligan, Amy Sainski-Nguyen, Cheng Wang, Caroline Henriques
Publikováno v:
Journal of Pharmaceutical Health Services Research. 11:133-140
Autor:
Cheng Wang, Caroline Henriques, Adrienne M Gilligan, Amy Sainski-Nguyen, Jessica Franchino-Elder, Briain O Hartaigh, Xue Song
Publikováno v:
Journal of Cardiology and Cardiovascular Sciences. 3:36-46
Autor:
Neil J. Shah, Reshma Shinde, Kristin Moore, Amy Sainski-Nguyen, Lisa Le, Feng Cao, Rui Song, Puneet Singhal, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 40:4528-4528
4528 Background: Approval of immuno-oncology (IO) agents have changed treatment paradigm for mRCC pts. While IO-based therapies have demonstrated improved survival, these can be associated with considerable HCRU and costs necessitating their examinat
Autor:
David D, Stenehjem, Claire, Telford, Sudhir K, Unni, Hillevi, Bauer, Amy, Sainski, Rishi, Deka, Marisa B, Schauerhamer, Xiangyang, Ye, Casey R, Tak, Junjie, Ma, Tapashi B, Dalvi, Lia, Gutierrez, James A, Kaye, Jerzy E, Tyczynski, Diana I, Brixner, Joseph E, Biskupiak
Publikováno v:
Breast cancer research and treatment. 186(3)
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Cynthia Matossian,1 Xue Song,2 Ishveen Chopra,2 Amy Sainski-Nguyen,2 Abayomi Ogundele3 1Matossian Eye Associates, Doylestown, PA, USA; 2Outcomes Research, IBM Watson Health, Cambridge, MA, USA; 3Medical Affairs, Sun Pharmaceutical Industries, Inc., P
Autor:
Cheng Wang, Kathleen Wilson, Jessica Franchino-Elder, Xue Song, Adrienne M Gilligan, Stephen Sander, Caroline Henriques, Amy Sainski-Nguyen, David M. Smith
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 19:203-212
This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients initiating oral anticoagulants.Ad
Autor:
Cheng Wang, Amy Sainski-Nguyen, Caroline Henriques, Adrienne M Gilligan, David M. Smith, Stephen Sander, Kathleen Wilson, Jessica Franchino-Elder, Xue Song
Publikováno v:
Current Medical Research and Opinion. 34:285-295
Compare costs and healthcare resource utilization (HCRU) among newly-diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs apixaban, rivaroxaban, or warfarin.Newly-diagnosed adult NVAF patients initiating dabigat
Publikováno v:
BMJ Open
ObjectivesHidradenitis suppurativa (HS) causes substantial morbidity and quality-of-life impairment. We examined demographic/clinical characteristics of patients with HS and treatment patterns, prevalence and healthcare resource utilisation/expenditu